据天眼查APP显示，云南沃森生物技术股份有限公司成立于2001年01月16日，注册资本159934.8541万 人民币。（数据宝） 12月4日沃森生物大宗交易一览 | 成交量（万 | 成交金额（万 | 成交价格 | 相对当日收盘折溢价 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | 股） | 元） | （元） | （%） | 业部 | | | 60.40 | 704.87 | 11.67 | 0.00 | 机构专 | 中信证券股份有限公司上 | | | | | | 用 | 海分公司 | 证券时报·数据宝统计显示，沃森生物今日收盘价为11.67元，下跌0.77%，日换手率为1.10%，成交额为 1.99亿元，全天主力资金净流出2190.64万元，近5日该股累计下跌4.42%，近5日资金合计净流出1.34亿 元。 两融数据显示，该股最新融资余额为18.20亿元，近5日减少4353.12万元，降幅为2.34%。 （文章来源：证券时报网） 沃森生物12月4日大宗交易平台出现一笔成交，成交量60.40万股，成交金额704.87万元，大宗交易成交 价为11. ...

Core Viewpoint - Shenzhen Haohai Biotechnology Co., Ltd. has been established with a registered capital of 10 million RMB, focusing on the research and development of marine biological active substance extraction, purification, and synthesis technologies [1] Group 1: Company Overview - The legal representative of the company is Zhu Chengyi [1] - The company has a registered capital of 10 million RMB [1] Group 2: Business Scope - The general business scope includes research and development of marine biological active substances, biobased materials, and biobased material manufacturing and sales [1] - The company is also involved in the research and development of biological feed and organic fertilizers, as well as the sale of feed raw materials [1] - The company is permitted to produce health food, subject to relevant approvals [1]

Group 1 - The stock of Jindike (688670) closed at 30.50 yuan on December 3, with a significant increase of 15.93%, a turnover rate of 14.07%, and a trading volume of 486 million yuan [1] - The stock was listed on the daily trading list due to its price increase of 15% [1] - The top five trading departments accounted for a total transaction of 1.10 billion yuan, with a net sell of 38.18 million yuan [1][3] Group 2 - The main capital inflow for the stock was 69.24 million yuan throughout the day [2] - Over the past six months, the stock has appeared on the trading list six times, with an average price increase of 3.34% the day after being listed and an average increase of 1.57% in the following five days [3] Group 3 - The top buying department was Guojin Securities Co., Ltd. Shenzhen Branch, with a purchase amount of 13.35 million yuan, followed by Goldman Sachs (China) Securities with 6.71 million yuan [3] - The top selling department was Goldman Sachs (China) Securities, with a selling amount of 22.06 million yuan [3]

【编者按】外贸，是观察区域经济活力的重要窗口，更是河南构建新发展格局的关键支撑。在全球贸易 环境复杂多变、不确定性因素增多的当下，"稳外贸"不仅是稳增长、稳就业的重要抓手，更是河南企业 融入双循环、拓展国际市场的必由之路。如何帮助河南外贸企业在风浪中稳健前行，破解"有单不敢 接、有单无力接"的出海难题？出口信用保险无疑是关键的"护航者"与"助推器"。它既为企业防范海外 买家信用风险、应对贸易壁垒筑起"安全网"，也通过风险保障等支持，为企业大胆开拓新市场、抢抓新 订单注入"强心剂"。 正是基于助力河南外贸高质量发展和河南高水平开放的共同目标，中国出口信用保险公司河南分公司与 河南日报社财经全媒体中心、大河财立方携手推出《稳外贸 信保助力豫企出海》策划。通过走进一家 家深耕国际市场的河南企业，记录他们与信用保险"双向奔赴"的合作故事，挖掘信保工具如何为企业出 海"遮风挡雨"，如何赋能企业从"稳订单"到"拓市场"的进阶之路，为更多河南企业扬帆出海提供借鉴与 启发。 【大河财立方 记者 徐兵 文 李博 摄影】在国际贸易环境急速变化的当下，企业"走出去"早已不是比拼 价格与产品，更是一场关于风险管理、信用体系与全球资源 ...

Group 1 - The core point of the article is that Kanghua Biological announced a share reduction by a major shareholder, which may impact investor sentiment and stock performance [1][2] Group 2 - Kanghua Biological reported a revenue of 840 million yuan and a net profit attributable to shareholders of 189 million yuan for the first three quarters of 2025 [2] - The shareholder, Chuanfa Selected No. 3, reduced its holdings by 400,000 shares, accounting for 0.3056% of the company's total share capital [1][2]

Core Viewpoint - The recent acquisition of an 8% stake in the marketing service provider Sanrenxing (605168.SH) by prominent investor Yan Jianya marks a strategic move to enhance his capital matrix and strengthen industry resource integration [1][2]. Group 1: Investment and Shareholding - Yan Jianya will become the second-largest shareholder of Sanrenxing after acquiring the shares for a total price of 450 million yuan [1]. - The share transfer aims to introduce a significant strategic investor to optimize the shareholding structure of Sanrenxing [2]. - Prior to this acquisition, Yan Jianya and Sanrenxing had multiple collaborations, including Sanrenxing's successful exit from an investment in Yan's company, Juzhi Biotechnology, yielding a profit of over 15 million yuan [2]. Group 2: Business and Financial Performance - Sanrenxing has faced continuous revenue pressure, with projected revenue declining from 5.653 billion yuan in 2022 to 4.208 billion yuan in 2024, and net profit dropping from 736 million yuan to 123 million yuan during the same period [5]. - In the first three quarters of 2025, Sanrenxing reported revenue of 2.569 billion yuan and a net profit of 144 million yuan, continuing the downward trend [5]. Group 3: Yan Jianya's Broader Capital Strategy - Yan Jianya's capital strategy is supported by his control over two listed companies: Juzhi Biotechnology and Triangle Defense (300775), which form the core of his capital base [6][7]. - Juzhi Biotechnology, known as the "first stock of collagen," has shown consistent high growth, with projected revenue of 5.539 billion yuan and net profit of 4.547 billion yuan in 2024 [6]. - Triangle Defense has maintained stable profitability, reaching a peak in earnings in 2023, and is a key supplier in the aerospace sector [6][7]. Group 4: Investment Landscape and Future Prospects - Yan Jianya's ambitions extend beyond listed companies, with investments in various sectors including consumer goods and military industry, aiming for a systematic investment layout around related industrial chains [10][13]. - His private equity firm, Sanyuan Capital, manages funds focused on aerospace, new materials, and advanced manufacturing, with a scale of 1 to 2 billion yuan [13]. - Yan Jianya has also invested in several aerospace and new materials companies, further diversifying his investment portfolio [13].

市公司 时时彩公司书 | 市场数据: | 2025 年 12 月 02 日 | | --- | --- | | 收盘价（元） | 24.45 | | 一年内最高/最低（元） | 32.49/11.05 | | 市净率 | 22.8 | | 股息率%（分红/股价） | | 2025年09月30日 其研教程· 每股净资产 (元) 1.07 | 资产负债率% | 24.41 | | --- | --- | | 总股本/流通 A 股 (百万) | 274/180 | | 流通 B 股/H 股 (百万) | -/- | 年内股价与大盘对比走势： 相关研究 证券分析师 刘靖 A0230512070005 liujinq@swsresearch.com 王雨晴 A0230522010003 wangyq@swsresearch.com 題首德 (920047) — NL005Ⅱc 期临床试验启动在即，增添成长动能 事件: 近日，公司官网发布新闻，由公司自主研发的治疗用生物制品 1 类新药重组人胸腺素β4（代 ● 号 NL005）用于治疗急性心肌梗死（AMI）IIc 期临床研究方案完成与 CDE 的临床试验前沟 通会,公司将 ...

Core Viewpoint - Shengnuo Bio announced that its wholly-owned subsidiary Chengdu Kaijie Peptide Technology Co., Ltd. has recently obtained the registration of the cosmetic raw material Pentapeptide-18 from the National Medical Products Administration, indicating a significant advancement in the company's product offerings in the cosmetic industry [1] Group 1: Product Development - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products [1] - The safe usage level of Pentapeptide-18 in finished cosmetic products can reach 1.86% [1] - The ingredient aids in improving skin irritation conditions, thereby achieving skin protection [1]

Core Viewpoint - Shengnuo Bio (688117.SH) announced that its wholly-owned subsidiary Chengdu Kaijie Peptide Technology Co., Ltd. has successfully registered a new cosmetic ingredient, Pentapeptide-18, with the National Medical Products Administration, indicating a significant advancement in the company's product offerings in the cosmetic sector [1] Group 1: Company Developments - The new cosmetic ingredient Pentapeptide-18 is a skin protectant that can be used in various cosmetic products [1] - The safe usage concentration of Pentapeptide-18 in finished cosmetic products can reach up to 1.86% [1] - The ingredient is designed to assist in improving skin irritation conditions, thereby achieving skin protection [1]

Group 1 - The core point of the article is that Shengnuo Bio's subsidiary, Chengdu Kaijie Peptide Technology Co., Ltd., has successfully registered a new cosmetic ingredient, Pentapeptide-18, with the National Medical Products Administration [1] - Pentapeptide-18 is a skin protectant that can be used in various cosmetic products, with a safe usage level of up to 1.86% in finished products [1] - The approval of Pentapeptide-18 will enhance the company's product portfolio and expand the application scenarios for beauty peptide products, positively impacting the company's business development [1]